Bausch Health Cos (NYSE:BHC) & Journey Medical (NASDAQ:DERM) Head-To-Head Comparison

Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Valuation & Earnings

This table compares Bausch Health Cos and Journey Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27 billion	0.22	$157.00 million	($2.96)	-2.06
Journey Medical	$61.86 million	2.73	-$11.43 million	($0.22)	-27.25

Bausch Health Cos has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bausch Health Cos and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Journey Medical	-8.95%	-20.23%	-6.60%

Analyst Ratings

This is a summary of current ratings and recommmendations for Bausch Health Cos and Journey Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1	5	0	1	2.14
Journey Medical	1	1	2	0	2.25

Bausch Health Cos currently has a consensus price target of $8.00, indicating a potential upside of 31.26%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 133.53%. Given Journey Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Journey Medical is more favorable than Bausch Health Cos.

Risk & Volatility

Bausch Health Cos has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 7.2% of Journey Medical shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Journey Medical beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

About Bausch Health Cos

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.